IHL.AX Incannex Healthcare (ASX) A$0.041 intraday 13 Mar 2026: Phase 2 news drives volume

IHL.AX stock opened the ASX session at A$0.047 and trades A$0.041 intraday on 13 Mar 2026 as volume spikes to 61,360,016 shares. The move follows two company announcements: statistically significant Phase 2 results for IHL-42X and a US$10.0 million registered direct offering that funds the next dose-optimization study. Traders are watching clinical milestones and cash runway closely today. We track price action, fundamentals and catalysts for short-term and multi-stage investors.

Intraday activity and most active trading

IHL.AX stock is among the ASX most active names this intraday session. Price sits at A$0.041 with a day range A$0.041–A$0.051 and a one-day change of -10.87%. Volume of 61,360,016 shares equals a relative volume of 9.55, well above the 50-day average of 6,427,691.00. High turnover reflects both institutional interest and retail reaction to clinical and financing headlines.

High liquidity today raises short-term trade opportunities but also increases volatility. Market participants should note the low float and 347,705,540 shares outstanding, which can amplify intraday moves.

Clinical catalysts: IHL-42X Phase 2 impact on IHL.AX stock

Incannex reinforced the development path for IHL-42X after Phase 2 showed statistically significant benefits on key endpoints. The program secured FDA Fast Track designation and a planned Phase 2 crossover dose-optimization study, DReAMzz, ahead of a streamlined Phase 3. The clinical news is a primary driver of today’s trading and underpins medium-term upside if subsequent studies confirm results. Read the release for details.

Clinical outcomes reported: up to 83% AHI reduction in a responder, and population responses of 33.3% (low dose) and 41.2% (high dose) for >30% AHI reduction. The safety profile showed no serious adverse events, which supports tolerability in later trials.

Financing and capital runway affecting IHL.AX stock

Incannex priced a US$10.0 million registered direct offering to fund the DReAMzz Phase 2 study. The offering issues 2,000,000 shares plus warrants at a combined price of US$5.00 per unit. If warrants are fully exercised, the company could raise up to US$23.0 million in total proceeds. The financing materially reduces near-term dilution risk from ATM facilities and secures funding for the next development milestone. Financing details.

Management expects existing cash plus the new proceeds to fund DReAMzz, leaving cash on hand for Phase 3 planning into 2027.

Financials, valuation and sector context for IHL.AX stock

IHL.AX trades with a market cap of A$14,255,927.00 and cash per share of A$0.0217. Trailing EPS is -1.30 and PE is negative. Key ratios: price-to-book 0.75, price-to-sales 14.06, and current ratio 9.02, indicating a strong short-term liquidity position. Research and development expense runs high relative to revenue with R&D-to-revenue near 9.24x, reflecting a clinical-stage profile.

Within the ASX Healthcare sector, IHL.AX stock sits below sector averages for market cap and liquidity. Sector peers show stronger revenue and ROE metrics, making valuation and binary clinical risk central to stock performance.

Technical snapshot and trading signals for IHL.AX stock

Price sits below its 50-day average A$0.065 and 200-day average A$0.103, showing a downtrend on longer timeframes. Short-term support equals the year low at A$0.041. Relative volume and a large intraday range suggest momentum traders are active. On a breakout above A$0.060, traders may re-test the 50-day average. Conversely, a failure to hold A$0.041 could invite stop-driven selling.

Liquidity and the low unit price increase risk of wide spreads. Use limit orders and position sizing to manage execution risk.

Meyka AI grade, forecast and analyst-style price targets

Meyka AI rates IHL.AX with a score of 64.99 out of 100 — Grade B, suggestion HOLD. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. This score does not constitute financial advice.

Meyka AI’s forecast model projects a base-case price of A$0.12 for IHL.AX stock, implying an upside of +192.68% versus the current A$0.041. We present a conservative target of A$0.06, base A$0.12, and upside A$0.20 as scenario ranges. Forecasts are model-based projections and not guarantees.

Final Thoughts

IHL.AX stock is trading as one of the ASX most active names intraday on 13 Mar 2026, driven by positive Phase 2 results for IHL-42X and a US$10.0 million financing. The clinical progress and FDA Fast Track designation are clear near-term catalysts. The registered direct offering reduces immediate funding risk and funds the DReAMzz dose-optimization study, which could de-risk a Phase 3 program if outcomes hold. Valuation reflects a clinical-stage company with negative EPS and high R&D spending, while liquidity and low unit price increase volatility. Meyka AI’s base forecast at A$0.12 implies substantial upside, but investors should weigh binary clinical risk and potential dilution. For traders, watch intraday volume, the A$0.041 support, and any updates on dosing timelines. For longer-term investors, monitor DReAMzz results and the company’s path to Phase 3. See the official clinical release and financing notice for source details and full disclosures. IHL.AX on Meyka

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.